Recent Publications

1. Micevic, G., Muthusamy, V., Damsky, W., Theodosakis, N., Liu, X., Meeth, K., Wingrove, E., Santhanakrishnan, M., and Bosenberg, M. (2016). DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell reports 14, 2180-2192.

2. Meeth, K., Wang, J.X., Micevic, G., Damsky, W., and Bosenberg, M.W. (2016). The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment cell & melanoma research 29, 590-597.

3. Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D.P., Santhanakrishnan, M., Erdelyi, I., Platt, J.T., Huang, L., Theodosakis, N., et al. (2015). mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer cell 27, 41-56.

4. Theodosakis, N., Held, M.A., Marzuka-Alcala, A., Meeth, K.M., Micevic, G., Long, G.V., Scolyer, R.A., Stern, D.F., and Bosenberg, M.W. (2015). BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular cancer therapeutics 14, 1680-1692.

5. Damsky, W.E., Curley, D.P., Santhanakrishnan, M., Rosenbaum, L.E., Platt, J.T., Gould Rothberg, B.E., Taketo, M.M., Dankort, D., Rimm, D.L., McMahon, M., et al. (2011). beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer cell 20, 741-754.

6. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E., Jr., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature genetics 41, 544-552.